COMPASS Pathways Plc American Depository Shares

Trump's April 2026 executive order supporting psychedelic drugs has boosted the psychedelics industry. The FDA awarded priority vouchers to select companies, accelerating drug review timelines. Three biotech firms—Compass Pathways, AtaiBeckley, and Definium Therapeutics—have seen significant stock surges. While analysts remain bullish with hi...

An executive order fast-tracking psychedelic medicines to market has bifurcated the alternative drug sector. Psychedelic stocks like Compass Pathways and Atai Beckley surged 40% and 20% respectively due to regulatory tailwinds and short squeezes, while mature cannabis operators like Curaleaf and Innovative Industrial Properties are now valued as ...

Compass Pathways stock surged over 40% following a White House Executive Order aimed at accelerating approval of psychedelic drug treatments for mental health. The company's COMP360 synthetic psilocybin therapy has completed two positive phase 3 trials for treatment-resistant depression and is now on a faster regulatory track with the FDA.

President Trump signed an executive order to fast-track FDA approval of psychedelic treatments for mental disorders, reducing review times from 6-10 months to 1-2 months. The order also allocates $50 million for private sector research. Three biotech companies with breakthrough therapy designations saw significant stock gains following the announ...

Psychedelic therapy is emerging as a transformative treatment model for mental health conditions, particularly treatment-resistant depression and PTSD. Unlike daily medications, psychedelic therapy is an interventional approach administered 1-6 times with durable long-term benefits. Companies like Compass Pathways are advancing FDA trials, while ...